Efficacy of Levetiracetam Monotherapy in Childhood Epilepsy

Basit Öğe Kaydı
dc.authoridKılıç, Betül/0000-0003-0884-2635
dc.authoridARSLAN, MÜJGAN/0000-0002-0486-3431;
dc.authorwosidKılıç, Betül/ABS-2287-2022
dc.authorwosidARSLAN, MÜJGAN/AAN-5584-2021
dc.authorwosidArslan, Müjgan/AAN-5580-2021
dc.contributor.authorArslan, Mujgan
dc.contributor.authorGungor, Serdal
dc.contributor.authorKilic, Betul
dc.date.accessioned2024-08-04T20:10:30Z
dc.date.available2024-08-04T20:10:30Z
dc.date.issued2017
dc.departmentİnönü Üniversitesien_US
dc.description.abstractObjectives: Levetiracetam (LEV) is an antiepileptic drug approved particularly for treatment of focal seizures. The aim of this study was to investigate efficacy and tolerability of LEV monotherapy in pediatric patients. Methods: In the present study, records of 225 children (aged 1 month-18 years) treated with LEV and with follow-up for at least 1 year were evaluated. Diagnosis of epilepsy included history of 2 or more unprovoked seizures. Demographic characteristics, reason for antiepileptic treatment, dosage of levetiracetam, duration of treatment, antiepileptic drugs used previously, seizure type, seizure duration, cranial magnetic resonance images, electroencephalogram results, seizure etiology, and side effects of the drug were documented. Results: Total of 225 patients, 95 girls and 130 boys, were enrolled in the study. Of those, 125 (55.6%) patients had generalized seizures, 90 (40%) had focal seizures, and 10 (4.4%) had other type of seizures. In treatment, 186 (82.7%) patients remained seizure-free. There was no difference in effectiveness of LEV on partial or generalized epilepsy. Overall, 8 (18%) patients had adverse events. Most common side effects observed were irritability and nervousness. There was no relationship between drug dosage and side effects. Conclusion: LEV monotherapy is effective in childhood epilepsy with focal or generalized seizures. It is well tolerated in spite of mild and transient side effects, which do not require drug discontinuation.en_US
dc.identifier.doi10.14744/epilepsi.2016.22043
dc.identifier.endpage18en_US
dc.identifier.issn1300-7157
dc.identifier.issue1en_US
dc.identifier.startpage13en_US
dc.identifier.trdizinid286453en_US
dc.identifier.urihttps://doi.org/10.14744/epilepsi.2016.22043
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/286453
dc.identifier.urihttps://hdl.handle.net/11616/92809
dc.identifier.volume23en_US
dc.identifier.wosWOS:000404806200004en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherKare Publen_US
dc.relation.ispartofEpilepsien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectChilden_US
dc.subjectefficacyen_US
dc.subjectepilepsyen_US
dc.subjectlevetiracetamen_US
dc.subjectmonotherapyen_US
dc.subjectsafetyen_US
dc.titleEfficacy of Levetiracetam Monotherapy in Childhood Epilepsyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu